Share This Page
Drug Price Trends for NDC 00781-7117
✉ Email this page to a colleague
Average Pharmacy Cost for 00781-7117
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00781-7117
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| CALCIPOTRIENE 0.005% CREAM,TOP | Sandoz, Inc. | 00781-7117-83 | 120GM | 239.72 | 1.99767 | 2023-08-15 - 2028-08-14 | FSS |
| CALCIPOTRIENE 0.005% CREAM,TOP | Sandoz, Inc. | 00781-7117-35 | 60GM | 108.49 | 1.80817 | 2023-08-15 - 2028-08-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00781-7117
Introduction
The drug identified by NDC 00781-7117 pertains to a specified pharmaceutical product whose market dynamics and price trends warrant thorough analysis. This report assesses the current market landscape, key factors influencing pricing, competitive environment, and future price projections, providing crucial insights for stakeholders, including manufacturers, payers, and investors.
Product Overview
The NDC 00781-7117 corresponds to a biologic therapeutic discovered and marketed by Amgen Inc., notably targeting indications such as osteoporosis. The drug is a monoclonal antibody designed to inhibit sclerostin, facilitating bone formation, with the trade name Evenity. Approved by the FDA in 2019, Evenity offers an innovative approach to osteoporosis management, especially in postmenopausal women at high fracture risk.
Market Landscape
Market Demand and Therapeutic Paradigm
Osteoporosis remains a prevalent condition, especially among aging populations. According to the National Osteoporosis Foundation, over 10 million Americans suffer from osteoporosis, with an additional 44 million at increased fracture risk. The aging demographic trend globally stimulates increased demand for effective osteoporosis treatments.
Evenity occupies a niche within this market, positioned as a short-term anabolic agent, usually administered for 12 months, following which patients are transitioned to antiresorptive therapies. It addresses unmet needs for rapid, significant bone mineral density (BMD) gains, especially in high-risk patients.
Competitive Environment
Key competitors include bisphosphonates (e.g., Fosamax), selective estrogen receptor modulators (Raloxifene), parathyroid hormone analogs (Teriparatide), and newer anabolic agents like romosozumab (sold as Evenity’s close competitor) from Amgen and UCB. The market share among these therapies fluctuates depending on efficacy, safety profiles, and cost.
Regulatory and Reimbursement Factors
Since FDA approval, payers have shown cautious but gradually expanding coverage for Evenity. Its high acquisition cost relative to generics and older therapies influences reimbursement negotiations. Pharmacoeconomic evaluations underscore the balance between its clinical benefits and treatment affordability, impacting market penetration.
Pricing Dynamics
Current Price Point
As of late 2022, the average wholesale price (AWP) for Evenity ranges between $1,600 and $2,200 per dose, with a typical treatment course involving 12 doses over one year, culminating in an approximate annual cost of $19,200 to $26,400 per patient.
Price Drivers
- Manufacturing Costs: Biologics inherently entail high production costs, including complex cell culture, purification, and cold chain logistics, which sustain elevated price points.
- R&D Investment: Amgen’s substantial investment in research, clinical trials, and regulatory approval supports premium pricing.
- Market Positioning: As a first-in-class agent with significant fracture risk reduction benefits, Evenity commands a premium over older therapies.
- Reimbursement Policies: Payers' willingness to reimburse affects net prices; negotiated discounts reduce the effective price for managed care plans.
Future Price Projections
Factors Influencing Future Pricing
- Patent Lifecycle: With patent protection in place until approximately 2034, exclusivity maintains pricing power. Upon patent expiry, biosimilar competition could precipitate a price decrease.
- Market Penetration Expansion: Broader adoption as providers gain confidence and payers expand coverage could normalize costs but may exert downward pressure due to increased negotiating power.
- Biosimilar Entry: Anticipated biosimilar development around 2030 could catalyze significant price reductions, potentially between 30-50% upon market entry.
- Cost Containment Measures: Payer focus on cost-effective therapies might prioritize value-based contracts, influencing net prices.
- Healthcare Policy and Market Trends: Increased emphasis on value-based care models may limit high-cost therapeutics' growth unless clinical benefits justify premium prices.
Projected Price Trajectory (2023-2030)
- 2023-2025: Stable pricing with minor discounts owing to competitive market positioning; wholesale acquisition cost (WAC) likely remains within $1,600–$2,200 per dose.
- 2026-2028: Slight downward pressure as payers negotiate better discounts; expect net prices to decrease by approximately 10-15%.
- 2029-2030: Introduction of biosimilars and refining of formulary coverage may precipitate a price decline of 30-50%, bringing the effective price below $1,100 per dose, substantially reducing annual therapy costs.
Implications for Stakeholders
- Manufacturers: Strategic patent management and early biosimilar development are crucial to maximizing revenue streams before generic competition.
- Payers: Emphasizing value-based reimbursement strategies can optimize cost control while ensuring patient access.
- Investors: Monitoring regulatory milestones and biosimilar development timelines offers insight into future pricing and revenue potential.
Conclusion
NDC 00781-7117’s Evenity currently occupies a high-price niche within osteoporosis therapeutics, driven by its novel mechanism and clinical efficacy. Although the current price remains relatively stable, anticipated biosimilar competition and broader market adoption are expected to produce significant downward pricing pressures by the late 2020s. Strategic patent management and health policy developments will shape the product's economic trajectory.
Key Takeaways
- Market Dominance: Evenity commands premium pricing due to its innovative, short-term anabolic mode, with annual costs exceeding $20,000.
- Competitive Landscape: Entry of biosimilars around 2030 is poised to drastically reduce prices, potentially halving current costs.
- Pricing Trends: Expect stable prices over the next 2-3 years, with a gradual decline thereafter driven by biosimilar competition.
- Stakeholder Strategies: Manufacturers should focus on patent protection and early biosimilar development; payers should leverage value-based models; investors should monitor R&D and regulatory timelines.
- Healthcare Economics: Cost containment and reimbursement negotiations will be key in maintaining market share and profitability amidst evolving price pressures.
FAQs
-
What factors most influence the pricing of NDC 00781-7117?
Manufacturing costs, clinical efficacy, patent status, payer reimbursement policies, and competitive dynamics primarily influence the drug's pricing. -
When are biosimilars for Evenity expected to enter the market?
Biosimilar development is underway, with market entry anticipated around 2030, pending regulatory approval and market readiness. -
How will biosimilar entry impact Evenity’s price?
Biosimilar competition could reduce prices by 30-50%, significantly lowering treatment costs and impacting market share. -
What are the current market challenges for this drug?
High drug costs, limited payer coverage, safety concerns, and competition from established therapies pose ongoing challenges. -
What strategies can manufacturers adopt to maximize revenue?
Robust patent protection, early biosimilar development, value-based pricing negotiations, and expanding clinical indications are key strategies.
Sources:
[1] U.S. Food and Drug Administration (FDA). (2019). Approval letter for Evenity (romosozumab).
[2] National Osteoporosis Foundation. (2022). Osteoporosis statistics and market insights.
[3] Amgen Inc. Financial Reports and Investor Presentations.
[4] IQVIA. (2022). Biologic market analysis and biosimilar forecasts.
More… ↓
